CeQur Simplicity News & Media

Media Resources

Recent CeQur Company News

CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and Medtronic, Inc.
  • Keywords: CEO, CeQur, leadership, commercialization
News Release Image
Open Press Release
CeQur® announced the appointment of Peter B. Luther to its board of directors, effective immediately. Luther is a 29-year veteran of the medical device and diagnostics, OTC drugs and consumer-packaged goods industries.
  • Keywords: Advisor, CeQur, Commercialization, PAQ MEAL, PAQ TOTAL
News Release Image
Open Press Release
The Journal of Diabetes Science and Technology paper summarizes data from multiple studies of the PAQ basal-bolus insulin delivery device and how it helps overcome barriers to insulin delivery to meet the needs of people with type 2 diabetes and their healthcare providers.
  • Keywords: JDST, PAQ, basal-bolus, studies
News Release Image
Open News Release Open Link
The Journal of Health Economics and Outcomes Research published findings from a long-term cost-effectiveness evaluation of continuous subcutaneous insulin infusion (CSII) with CeQur’s PAQ® Insulin Delivery Device as compared to multiple daily insulin injections (MDI) for people with type 2 diabetes.
  • Keywords: JHEOR, cost-effectiveness, insulin
Open News Release Open Link
CeQur® today announced that the journal Diabetic Medicine published the findings from two studies evaluating the company’s PAQ® Insulin Delivery Device among people with type 2 diabetes. The data demonstrate that the simple three-day, wearable PAQ basal-bolus insulin delivery device significantly improved glycemic control among people with type 2 diabetes who transitioned to the device. Study participants also reported increased treatment satisfaction with the PAQ basal-bolus insulin device as compared to insulin injections.
  • Keywords: PAQ, basal-bolus, insulin, device
Open News Release Open Link
CeQur® today announced that the company has acquired select assets of Calibra Medical, Inc., one of the Johnson & Johnson Diabetes Care Companies. The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime.
  • Keywords:
News Release Image
Open Press Release
View Less CeQur News

CeQur In The Media

These articles are not controlled by CeQur, but you may find them useful to learn more about diabetes and CeQur.

ADA PosterJune 16, 2020
"High Treatment Satisfaction with 3-day Insulin Patch is Independent of Patient Demographics: A Post-Hoc Analysis" — a presentation at the American Diabetes Association 80th Scientific Sessions

Play Presentation Download Slides

ArticleJune 6, 2019
The Wider View: With new CEO in place, CeQur primed to PAQ a punch in diabetes market

Open External Link

ArticleJune 5, 2019
CeQur CEO Robert Farra transitions to chief technology officer, succeeded by Bradley Paddock

Open External Link

ArticleJuly 19, 2018
Two New 'Wearable Pen' Insulin Devices Coming Soon

Open External Link

Media Kit

Our media kit is designed for the press and media. Rollover (or mobile tap) the images below and select the link for the colors and format of the product images and logo you want. CeQur maintains all copyrights to these images and files. For more information please contact our Corporate Communications Office at media@cequr.com.

Product Images

Product and Company Logos


For easy reference, CeQur corporate and product colors are:

HEX #002F6C
RGB 0, 47, 108
HEX #006298
RGB 0, 98, 152
RGB 187, 188, 188
Light Blue
HEX #00A3E1
RGB 0, 163, 225
RGB 255, 103, 31
RGB 255, 184, 28
HEX #61A944
RGB 97, 169, 68